Vela Bio (603739): R&D-driven strategy continues to deepen, building an integrated 'industry + service' empowerment platform.

The company's revenue and net profit showed steady growth in 2025 and the first quarter of 2026. In 2025, the company achieved a revenue of 1.366 billion yuan, representing a year-on-year increase of 3.43%, and a net profit attributable to shareholders of 70 million yuan, reflecting a year-on-year increase of 11.45%. In 202

Guosen SecuritiesMay 8 14:57

Vela Bio (603739): Revenue Grows Steadily, Achievements in International Expansion Become Evident

Event: The company released its 2025 annual report. In 2025, the company achieved operating revenue of 1.366 billion yuan, representing a year-on-year increase of 3.43%; net profit attributable to shareholders reached 70 million yuan, reflecting a year-on-year growth of 11.45%. The company...

Southwest SecuritiesApr 27 00:00

Vela Bio (603739): Solid core business performance, multi-track synergy to empower future growth

On April 24, 2026, Weilan Bio officially released its annual report for 2025 and the first-quarter report for 2026. In 2025, the company achieved a total operating revenue of 1.366 billion yuan, representing a year-on-year increase of 3.4%.

中邮证券Apr 27 00:00

Vela Bio's 2025 net profit attributable to shareholders reached 69.81 million yuan, up 11.45%, while the non-recurring net profit declined by 22.64%, highlighting pressure on core business profitability.

In 2025, the company's revenue and net profit attributable to shareholders increased by 3.43% and 11.45%, respectively. However, the non-recurring net profit fell by 22.64%, indicating pressure on core business profitability. Non-recurring gains reached RMB 50.35 million, accounting for 72.13% of the net profit attributable to shareholders. Government subsidies and litigation reversals combined have already exceeded the total net profit. Operating cash flow declined by 41.69% year-on-year, gross margin slightly decreased, enzyme preparation revenue dropped by 7.23%, and overseas expansion remained weak.

lanjinger.comApr 25 17:01

Summary of the 2025 Annual Report of Qingdao Weilan Biological Co., Ltd.

SZSIApr 25 00:00 · Announcements

Q1 2026 Report of Qingdao Weilan Biological Co., Ltd.

SZSIApr 25 00:00 · Announcements